Two cholesterol drugs for heart disease prevention
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a history of heart disease, stroke, or imaging evidence of clogged arteries (from prior angiography, CT scan, or ultrasound)
- You cannot tolerate or have a contraindication to statin therapy (the standard first-line cholesterol drug)
- Your fasting LDL cholesterol is between 2.5 and 5.0 mmol/L at screening
- You have been on stable cholesterol-lowering background therapy (such as ezetimibe) for at least 4 weeks before joining
- You have not previously taken any PCSK9 inhibitor medication (alirocumab, evolocumab, or inclisiran)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
This study tests a new medicine called inclisiran (a small interfering RNA) to see if it can shrink or stabilize fatty plaques in neck arteries. You may qualify if you have carotid plaques and high LDL cholesterol despite statin use or if you haven't taken statins.
This study looks at how to best coordinate care between your regular doctor and heart specialists if you have chronic heart disease. It tests whether a special program helps you stay on the right medications to lower cholesterol.
This trial tests a new version of inclisiran, a cholesterol-lowering medicine, to see if it is safe and works well. The study compares it to the current version. You may qualify if you have moderately high cholesterol but have never taken cholesterol medications.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.